Yehezkel Ben-Ari
Director/Board Member at Institut National de la Santé & de la Recherche Médicale
Profile
Yehezkel Ben-Ari is the founder of Neurokin SA, which was founded in 2003.
He held the title of Director from 2003 to 2014.
Currently, he is the Director at Institut National de la Santé & de la Recherche Médicale.
Yehezkel Ben-Ari active positions
Companies | Position | Start |
---|---|---|
Institut National de la Santé & de la Recherche Médicale
Institut National de la Santé & de la Recherche Médicale Miscellaneous Commercial ServicesCommercial Services Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France. | Director/Board Member | 20/11/2009 |
Former positions of Yehezkel Ben-Ari
Companies | Position | End |
---|---|---|
Neurokin SA
Neurokin SA BiotechnologyHealth Technology Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage. | Founder | 11/03/2014 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
Neurokin SA
Neurokin SA BiotechnologyHealth Technology Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage. | Health Technology |
Institut National de la Santé & de la Recherche Médicale
Institut National de la Santé & de la Recherche Médicale Miscellaneous Commercial ServicesCommercial Services Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France. | Commercial Services |
- Stock Market
- Insiders
- Yehezkel Ben-Ari